VVT Medical Announces FDA Clearance of ScleroSafe System
Thursday, June 22, 2023
VVT Medical has recently announced that it has received a 510(k) clearance for its ScleroSafe™ platform from the U.S. Food and Drug Administration (FDA).
ScleroSafe™ is an innovative medical device designed to provide a streamlined and effective approach to treating and managing varicose veins in superficial veins. It stands out due to its unique features and capabilities. Utilising a non-thermal, non-tumescent (NT-NT) technique, ScleroSafe™ offers an efficient alternative for varicosity treatment.
ScleroSafe™ platform has the potential to revolutionise the treatment of varicose veins, offering patients a safe, effective, and user-friendly option. It has the ability to make a significant positive impact on the lives of numerous individuals not only in the United States but also globally.
By integrating injection and aspiration into one synchronised motion, ScleroSafe™ optimises the treatment process, enhancing efficiency and reducing complexity.
ScleroSafe™ has received approval in various regions, including Europe, Australia, Southeast Asia, and South America.